HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis
Viruses · 2024
DOI: 10.3390/v16121808 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Viruses, 2024. Verfasst von Paloma Gonçalves und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisbon, Portugal. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European & Developing Countries Clinical Trials Partnership, FCT - Fundação para a Ciência e a Tecnologia, FCT - Fundação para a Ciência e a Tecnologia, I.P..
Abstract (Originalsprache)
This systematic review assessed the prevalence of transmitted and acquired HIV drug resistance (HIVDR) and the associated risk factors in Mozambique. A search of the PubMed, Cochrane, B-On, and Scopus databases up to December 2023 was conducted and included 11 studies with 1118 HIV-1 pol sequences. Drug resistance mutations (DRMs) to NNRTIs were found in 13% of the drug-naive individuals and 31% of those on ART, while NRTI resistance occurred in 5% and 10%, respectively. Dual-class resistance (NNRTI + NRTI) was detected in 2% of the drug-naive and 8% of ART-experienced individuals. DRMs to protease inhibitors (PIs) were found in 2% of the drug-naive and 5% of ART-experienced individuals. The rate of DRMs was significantly higher in Beira than in Maputo, as well as in pediatric patients than in adults and pregnant women. Subtype C predominated (94%) and was associated with lower viral loads and DRM rates as compared to the other subtypes. The high prevalence of DRMs, particularly to NNRTIs and NRTIs, highlights the need for ongoing surveillance and targeted interventions. These findings are critical for optimizing ART regimens and informing public health strategies in Mozambique, with particular attention to regions such as Beira and vulnerable populations such as pediatric patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisbon, Portugal.
- Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Quinta da Granja, 2829-511 Caparica, Portugal.
- Instituto Nacional de Saúde de Mozambique (INS), Estrada Nacional N1, Maputo 1102, Mozambique.
- Division of Infectious Disease and Tropical Medicine, University of Munich (LMU), Leopoldstraße 5, 80802 Munich, Germany.
- David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.
ORCID-Profile: Paloma Gonçalves, Paulo Mascarenhas, Arne Kroidl, W Chris Buck, Ilesh Jani, Nuno Taveira
Förderung
- European & Developing Countries Clinical Trials Partnership
- FCT - Fundação para a Ciência e a Tecnologia
- FCT - Fundação para a Ciência e a Tecnologia, I.P.
- European and Developing Countries Clinical Trials Partnership
- FCT–Fundação para a Ciência e a Tecnologia, I.P.
Zitieren
APA
Gonçalves, P., Mascarenhas, P., Marcelino, R., Mabunda, N., Kroidl, A., Buck, W. C., Jani, I., Palladino, C., & Taveira, N. (2024). HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis. Viruses. https://doi.org/10.3390/v16121808
Vancouver
Gonçalves P, Mascarenhas P, Marcelino R, Mabunda N, Kroidl A, Buck WC, et al. HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis. Viruses. 2024. doi:10.3390/v16121808
BibTeX
@article{Gonalves2024,
author = {Gonçalves, Paloma and Mascarenhas, Paulo and Marcelino, Rute and Mabunda, Nédio and Kroidl, Arne and Buck, W Chris and Jani, Ilesh and Palladino, Claudia and Taveira, Nuno},
title = {HIV-1 Antiretroviral Drug Resistance in Mozambique: A Systematic Review and Meta-Analysis},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121808}
}
EUVIMED